As discussed above, through NK cell-mediated immunoediting, selective pressure favors persistence of NK cell-resistant sarcoma cells expressing low levels of NKG2D and DNAM-1 ligands and high levels of MHC class I. Increasing the expression of NK cell-activating molecules on cancer cells, thus their sensitivity to NK cell-mediated lysis could serve as an important part of multimodal therapy in future sarcoma treatment. Here, CD226 is linked to sarcoma.